Endologix announced today that it acquired the Pounce thrombectomy system from Surmodics, closing the deal on May 18. Pounce, an FDA-cleared and commercially available fully mechanical thrombectomy platform, offers the non-surgical removal of thrombi and emboli from peripheral arteries. It comes in multiple configurations to support use across a … [Read more...] about Endologix acquires Pounce thrombectomy system from Surmodics
Cagent Vascular reports first-in-human IVL cases, closes $41M Series D
Cagent Vascular today announced the first-in-human cases with its Serranator Sonic IVL system alongside significant funding. In addition to the first human use of the intravascular lithotripsy (IVL) system, the company closed a $41 million Series D round. Serranator Sonic IVL's first human procedures took place in Uzbekistan as part of its … [Read more...] about Cagent Vascular reports first-in-human IVL cases, closes $41M Series D
Elixir Medical study backs DynamX bioadaptor against drug-eluting stent
Elixir Medical today announced four-year results from a study comparing its DynamX coronary bioadaptor system to a leading drug-eluting stent (DES). The BIOADAPTOR randomized controlled trial compared DynamX to the Medtronic Resolute Onyx DES, the current standard of care. It compared the therapies across Japan, Europe and New Zealand. … [Read more...] about Elixir Medical study backs DynamX bioadaptor against drug-eluting stent
Boston Scientific study of Seismiq coronary IVL meets endpoints
Boston Scientific (NYSE:BSX) today reported positive results from the FRACTURE study of its Seismiq intravascular lithotripsy (IVL) catheter. The pivotal FDA investigational device exemption (IDE) trial evaluates the use of the Seismiq 4CE coronary IVL catheter in the treatment of patients with severely calcified coronary artery disease … [Read more...] about Boston Scientific study of Seismiq coronary IVL meets endpoints
Stryker enrolls first patient in first-in-human study of AVS IVL in a coronary indication
Amplitude Vascular Systems (AVS), now part of Stryker (NYSE:SYK), today announced the first patient enrolled in a new study of its IVL technology. Stryker completed its acquisition of AVS, worth up to $835 million, earlier this month. The company develops intravascular lithotripsy (IVL) technology for treating severely calcified arterial … [Read more...] about Stryker enrolls first patient in first-in-human study of AVS IVL in a coronary indication
EmStop initiates IDE study of novel embolic protection device
EmStop announced today that it kicked off the CAPTURE-2 FDA investigational device exemption (IDE) study of its embolic protection system (EPS). CAPTURE-2 evaluates the safety and performance of the EPS, an investigational device for cerebral embolic protection designed to capture and remove debris that includes thrombus during commercially … [Read more...] about EmStop initiates IDE study of novel embolic protection device
Artivion closes $175M acquisition of aortic arch maker Endospan
Endospan announced today that Artivion completed its $175 million acquisition of the company, following FDA approval for its Nexus system. The FDA granted premarket approval (PMA) for the Nexus aortic arch system last month. Nexus treats aortic arch disease, including chronic aortic dissections, in patients at high risk for open surgical repair. … [Read more...] about Artivion closes $175M acquisition of aortic arch maker Endospan
Boston Scientific treats first patient with Seismiq IVL in ELEGANCE registry
Boston Scientific (NYSE:BSX) today announced the first patient treated with its Seismiq IVL system in the ELEGANCE registry. Dr. Michael R. Jaff, chief medical officer and VP of Peripheral Interventions at Boston Scientific, shared the news of the first IVL (intravascular lithotripsy) patient treated in the registry on LinkedIn. The ELEGANCE … [Read more...] about Boston Scientific treats first patient with Seismiq IVL in ELEGANCE registry
Rivermark Medical brings in $20M to support FloStent device for BPH
Andera Partners said today that it led a $20 million Series D financing round for urology-focused medical device maker Rivermark Medical. Rivermark Medical aims to redefine the treatment of benign prostatic hyperplasia (BPH) through its FloStent platform. It also picked up funding in the Series D from existing investors and an unnamed strategic … [Read more...] about Rivermark Medical brings in $20M to support FloStent device for BPH
Johnson & Johnson launches next-gen Shockwave IVL catheter
Johnson & Johnson (NYSE:JNJ) today announced the global launch of the Shockwave C2 Aero coronary intravascular lithotripsy (IVL) catheter. The next-generation catheter leverages Shockwave IVL's unique mechanism of action and the safety and effectiveness profile of its legacy catheters. It features improved deliverability, enhanced lesion … [Read more...] about Johnson & Johnson launches next-gen Shockwave IVL catheter
